Amgen, AZ Will Pilot FDA's Real-Time Clinical Trial Plan

Why It Matters

Real‑time data sharing could shave years off development timelines, giving patients faster access to promising therapies and reducing R&D costs for biotech firms.

Key Takeaways

• FDA launches real‑time clinical trial pilot with Amgen and AstraZeneca
• Pilot aims to replace sequential phases with continuous, adaptive trials
• AI-driven data sharing could cut drug development timelines by years
• First trials test Calquence combo for mantle‑cell lymphoma and Imdelltra for SCLC
• Paradigm Health’s framework already validated real‑time signal reporting

Pulse Analysis

The FDA’s real‑time clinical trial (RTCT) proposal marks a watershed moment for drug development, confronting a long‑standing bottleneck in early‑phase studies. By integrating artificial‑intelligence analytics into the data capture process, regulators can monitor safety signals and efficacy endpoints as they emerge, rather than waiting for a study’s formal closeout. This shift promises to reduce the latency that traditionally stretches drug approval timelines, aligning the United States with emerging global models that prioritize speed without compromising patient safety.

AstraZeneca and Amgen have volunteered as the inaugural participants, each launching a distinct pilot. AZ’s phase‑2 TrAVeRse trial combines its BTK inhibitor Calquence with AbbVie/Roche’s venetoclax and rituximab to treat treatment‑naïve mantle‑cell lymphoma, while Amgen’s phase‑1b STREAM‑SCLC evaluates the bispecific T‑cell engager Imdelltra for limited‑stage small‑cell lung cancer. Both studies will feed data continuously to the FDA through a reporting framework pioneered by Paradigm Health, which has already demonstrated technical feasibility. The pilots will test not only the technology but also new operational workflows that could replace the conventional sequential phase structure.

If successful, the RTCT model could reshape the entire clinical‑trial ecosystem. Continuous, adaptive trials would enable sponsors to pivot quickly based on emerging efficacy or safety trends, potentially collapsing the multi‑year gap between phases. This acceleration could lower R&D expenditures, improve capital efficiency, and most importantly, bring life‑saving treatments to patients sooner. However, the approach also raises questions about data integrity, patient consent management, and the regulatory capacity to evaluate streaming information. Ongoing feedback from the FDA’s request for information will be critical to refining the framework and ensuring that speed does not compromise rigor.